BackgroundCheck.run
Search For

Michele Pagano, 631 Washington Square Vlg APT 3N, New York, NY 10012

Known as:
Michelle Pagano
Related to:
Michael Pagano 63 Gregory A Pagano 79 Isabella Pagano 23

Michele Pagano Phones & Addresses

1 Washington Square Vlg APT 3N, New York, NY 10012    212-4732229   

131 Thompson St APT 7B, New York, NY 10012   

Boston, MA   

Get Report
Control this profile

Mentions for Michele Pagano

Michele Pagano resumes & CV records

Resumes

Michele Pagano Photo 33

Puppy Consultant

Location:
New York, NY
Work:
Ct Breeders
Puppy Consultant
Michele Pagano Photo 34

Chair, Department Of Biochemistry And Molecular Pharmacology

Location:
New York, NY
Industry:
Higher Education
Work:
New York University School of Medicine
Chair, Department of Biochemistry and Molecular Pharmacology New York University School of Medicine Sep 2005 - Sep 2015
Professor of Pathology Howard Hughes Medical Institute Sep 2005 - Sep 2015
Investigator New York University School of Medicine Sep 1999 - Sep 2005
Associate Professor New York University School of Medicine Sep 1999 - Sep 2005
Ellen and Gerald Ritter Professor of Oncology New York University School of Medicine Sep 1996 - Sep 1999
Assistant Professor Mitotix Nov 1992 - Aug 1996
Postdoctoral Fellow and Co-Founder Embl Aug 1990 - Nov 1992
Postdoctoral Fellow
Education:
Università Degli Studi Di Napoli Federico Ii 1980 - 1990
Doctor of Medicine, Doctorates, Medicine
Michele Pagano Photo 35

Michele Pagano

Work:
Nyu Langone Medical Center
Owner
Michele Pagano Photo 36

Marketing Programs Manager At Sparta Systems, Inc.

Location:
Greater New York City Area
Industry:
Computer Software
Michele Pagano Photo 37

Michele Pagano

Publications & IP owners

Wikipedia

Michele Pagano Photo 38

Michele Pagano

Michele Pagano (16971732) was an Italian painter of the late Baroque period, active in his natal city of Naples. Pagano flourished as a landscape painter or vedutista, but died in ...

Us Patents

Ubiquitin Ligases As Therapeutic Targets

US Patent:
6720181, Apr 13, 2004
Filed:
Aug 27, 1999
Appl. No.:
09/385219
Inventors:
Michele Pagano - New York NY
Esther Latres - New York NY
Assignee:
New York University - New York NY
International Classification:
C12N 500
US Classification:
435325, 4353201, 435 6, 514 231, 514 235
Abstract:
The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel ubiquitin ligases which modulate activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders.

Compounds Useful For The Treatment Of Cancer, Compositions Thereof And Methods Therewith

US Patent:
7037936, May 2, 2006
Filed:
Jun 16, 2003
Appl. No.:
10/463009
Inventors:
Jeffrey McKenna - San Diego CA, US
Frank Mercurio - San Diego CA, US
Veronique Plantevin - San Diego CA, US
Weilin Xie - San Diego CA, US
Michele Pagano - New York NY, US
Assignee:
Signal Pharmaceuticals, LLC. - San Diego CA
International Classification:
A61K 31/35
US Classification:
514451
Abstract:
The present invention generally relates to compounds and compositions useful for the modulation of ligase activity. The invention further relates to Compounds of the Invention, compositions thereof, and methods for treating or preventing cancer, a neoplastic disorder, acute or chronic renal failure, an inflammatory disorder, an immune disorder, a cardiovascular disease, an effect of aging or an infectious disease comprising administering an effective amount of a Compound of the Invention. The invention further relates to the use of a Compound of the Invention as a preservative of a cell, blood, tissue or an organ or as an agent to modulate stem cells.

Methods To Identify Compounds Useful For Tumor Sensitization To Dna Damage

US Patent:
7439032, Oct 21, 2008
Filed:
Oct 18, 2004
Appl. No.:
10/968871
Inventors:
Michele Pagano - New York NY, US
Assignee:
New York University - New York NY
International Classification:
G01N 33/53
US Classification:
435 78, 435 723
Abstract:
Cdc25A is herein identified as a substrate for β-TrCP1- or β-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with β-TrCP expression or function, or increasing β-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying β-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents.

Usp47 Inhibtors And Methods To Induce Apoptosis

US Patent:
8076309, Dec 13, 2011
Filed:
Apr 28, 2009
Appl. No.:
12/431336
Inventors:
Michele Pagano - New York NY, US
Jeffrey R. Skaar - New York NY, US
Angelo Peschiaroli - Rome, IT
N. Valerio Dorrello - Caivano, IT
Assignee:
New York University - New York NY
International Classification:
C12N 15/11
C07H 21/02
C07H 21/04
US Classification:
514 44, 536 231, 536 243, 536 2433, 536 245
Abstract:
The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.

Β-Trcp1, Β-Trcp2 And Rsk1 Or Rsk2 Inhibitors And Methods For Sensitizing Target Cells To Apoptosis

US Patent:
8093043, Jan 10, 2012
Filed:
Jun 4, 2009
Appl. No.:
12/478003
Inventors:
Michele Pagano - New York NY, US
Elinor Dehan - New York NY, US
Assignee:
New York University - New York NY
International Classification:
C12N 15/85
C07H 21/02
C07H 21/04
A61K 48/00
US Classification:
435325, 536 231, 536 245, 514 44
Abstract:
The invention relates to modulating BimEL levels (Bcl-2-Interacting Mediator of cell death, Extra Long isoform) to sensitize cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to increasing BimEL levels. In certain embodiments, the invention relates to inhibitors of at least one of β-TrCP1/2 or RSK1/2 proteins that sensitize tumor cells to chemotherapy-induced death or apoptosis. Additionally, the invention relates to cancer therapies, diagnostics, and methods for identifying novel drugs or drug candidates for increasing BimEL levels.

Methods To Identify Compounds Useful For The Treatment Of Proliferative And Differentiative Disorders

US Patent:
8119421, Feb 21, 2012
Filed:
Dec 5, 2008
Appl. No.:
12/315862
Inventors:
Michele Pagano - New York NY, US
Frank Mercurio - San Diego CA, US
Weilin Xie - San Diego CA, US
Angelo Peschiaroli - New York NY, US
Assignee:
New York University - New York NY
International Classification:
G01N 33/566
G01N 33/53
C12Q 1/00
C12Q 1/68
US Classification:
436501, 435 4, 435 6, 435 71
Abstract:
The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits. The present invention relates to screening assays that use novel and known substrate-targeting subunits of ubiquitin ligases to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel and known ubiquitin ligases which modulate activity of the novel and known ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative and differentiative disorders.

Modulating The Cdc14B-Cdh1-Plk1 Axis And Methods For Sensitizing Target Cells To Apoptosis

US Patent:
8216835, Jul 10, 2012
Filed:
Jul 8, 2009
Appl. No.:
12/499208
Inventors:
Michele Pagano - New York NY, US
Florian Bassermann - New York NY, US
Assignee:
New York University - New York NY
International Classification:
C12N 15/85
C07H 21/02
C07H 21/04
US Classification:
435325, 536 231, 536 245
Abstract:
The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and/or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders.

Usp47 Inhibitors And Methods To Induce Apoptosis

US Patent:
8318437, Nov 27, 2012
Filed:
Sep 28, 2011
Appl. No.:
13/247488
Inventors:
Michele Pagano - New York NY, US
Jeffrey R. Skaar - New York NY, US
Angelo Peschiaroli - Rome, IT
N. Valerio Dorrello - Caivano, IT
Assignee:
New York University - New York NY
International Classification:
C12Q 1/68
C12N 5/00
C12N 5/02
C07H 21/04
US Classification:
435 613, 435 617, 435 911, 435375, 536 245
Abstract:
The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.

Isbn (Books And Publications)

Cell Cycle: Materials And Methods

Author:
Michele Pagano
ISBN #:
0387580662

Cell Cycle: Materials And Methods

Author:
Michele Pagano
ISBN #:
3540580662

Possible Relatives

Cynthia S Pagano  David J Pagano  Dawn M Pagano  Debbie L Pagano  Danielle N Pagano  Dennis R Pagano  Diane M Pagano  Michele M Johnson  Michele Stanco  Michele S Standifer 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.